American Century Companies Inc. Purchases 366,653 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

American Century Companies Inc. increased its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 98.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 738,902 shares of the biopharmaceutical company’s stock after purchasing an additional 366,653 shares during the period. American Century Companies Inc. owned 1.53% of Puma Biotechnology worth $2,409,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the stock. Victory Capital Management Inc. bought a new stake in shares of Puma Biotechnology in the 2nd quarter valued at $54,000. SG Americas Securities LLC bought a new position in shares of Puma Biotechnology during the 1st quarter valued at about $57,000. Crestline Management LP lifted its holdings in shares of Puma Biotechnology by 6.5% during the 4th quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 2,135 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Puma Biotechnology by 2,309.9% during the 2nd quarter. Rhumbline Advisers now owns 50,270 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 48,184 shares in the last quarter. Finally, Lazard Asset Management LLC lifted its holdings in shares of Puma Biotechnology by 5,129.0% during the 1st quarter. Lazard Asset Management LLC now owns 49,466 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 48,520 shares in the last quarter. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Trading Up 0.8 %

NASDAQ PBYI opened at $2.58 on Friday. The business has a 50 day simple moving average of $2.93 and a 200 day simple moving average of $3.83. The stock has a market capitalization of $126.55 million, a P/E ratio of 7.82 and a beta of 1.09. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.32 and a quick ratio of 1.23. Puma Biotechnology, Inc. has a one year low of $2.13 and a one year high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The company had revenue of $47.10 million during the quarter, compared to the consensus estimate of $43.99 million. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.36%. During the same period last year, the firm earned $0.05 EPS. Research analysts expect that Puma Biotechnology, Inc. will post 0.25 earnings per share for the current year.

Insider Buying and Selling

In other Puma Biotechnology news, Director Michael Patrick Miller sold 23,358 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $3.49, for a total transaction of $81,519.42. Following the completion of the sale, the director now directly owns 47,000 shares of the company’s stock, valued at $164,030. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Michael Patrick Miller sold 23,358 shares of Puma Biotechnology stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $3.49, for a total transaction of $81,519.42. Following the completion of the transaction, the director now directly owns 47,000 shares of the company’s stock, valued at approximately $164,030. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Alan H. Auerbach sold 18,885 shares of the business’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $3.27, for a total transaction of $61,753.95. Following the completion of the sale, the chief executive officer now owns 7,085,435 shares of the company’s stock, valued at approximately $23,169,372.45. The disclosure for this sale can be found here. Insiders have sold 82,263 shares of company stock valued at $286,469 over the last quarter. Corporate insiders own 23.70% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on PBYI shares. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research note on Friday, August 2nd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.